1. Home
  2. YMAB vs ODV Comparison

YMAB vs ODV Comparison

Compare YMAB & ODV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YMAB
  • ODV
  • Stock Information
  • Founded
  • YMAB 2015
  • ODV 2005
  • Country
  • YMAB United States
  • ODV Canada
  • Employees
  • YMAB N/A
  • ODV N/A
  • Industry
  • YMAB Biotechnology: Pharmaceutical Preparations
  • ODV Precious Metals
  • Sector
  • YMAB Health Care
  • ODV Basic Materials
  • Exchange
  • YMAB Nasdaq
  • ODV Nasdaq
  • Market Cap
  • YMAB 386.7M
  • ODV 338.9M
  • IPO Year
  • YMAB 2018
  • ODV N/A
  • Fundamental
  • Price
  • YMAB $8.57
  • ODV $2.79
  • Analyst Decision
  • YMAB Buy
  • ODV
  • Analyst Count
  • YMAB 10
  • ODV 0
  • Target Price
  • YMAB $13.91
  • ODV N/A
  • AVG Volume (30 Days)
  • YMAB 2.2M
  • ODV 1.1M
  • Earning Date
  • YMAB 08-08-2025
  • ODV 08-12-2025
  • Dividend Yield
  • YMAB N/A
  • ODV N/A
  • EPS Growth
  • YMAB N/A
  • ODV N/A
  • EPS
  • YMAB N/A
  • ODV N/A
  • Revenue
  • YMAB $85,385,000.00
  • ODV $5,147,156.00
  • Revenue This Year
  • YMAB N/A
  • ODV $381.12
  • Revenue Next Year
  • YMAB $13.97
  • ODV $256.81
  • P/E Ratio
  • YMAB N/A
  • ODV N/A
  • Revenue Growth
  • YMAB N/A
  • ODV N/A
  • 52 Week Low
  • YMAB $3.55
  • ODV $1.16
  • 52 Week High
  • YMAB $16.11
  • ODV $2.91
  • Technical
  • Relative Strength Index (RSI)
  • YMAB 81.31
  • ODV 63.16
  • Support Level
  • YMAB $8.50
  • ODV $2.69
  • Resistance Level
  • YMAB $8.56
  • ODV $2.84
  • Average True Range (ATR)
  • YMAB 0.02
  • ODV 0.14
  • MACD
  • YMAB -0.12
  • ODV 0.01
  • Stochastic Oscillator
  • YMAB 83.33
  • ODV 76.89

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

About ODV Osisko Development Corp.

Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.

Share on Social Networks: